Krsnaa Diagnostics Q4 FY26 PAT Surges 102% to ₹417 Crore on Strong Revenue Growth
Krsnaa Diagnostics reported a 102% surge in Q4 FY26 PAT to ₹417 crore, up from ₹207 crore in Q4 FY25. Revenue increased by 4% to ₹1,926 crore. For FY25-26, PAT rose 31% to ₹1,013 crore on 8% higher revenue of ₹7,728 crore. NABH accreditation for radiology centres grew significantly.
The significant increase in Profit After Tax (PAT) and revenue, coupled with strategic expansion plans and operational improvements, are material developments that are likely to have a high impact on investor sentiment and the company's market position.
The company reported strong growth in PAT and revenue for both the quarter and the full fiscal year, indicating positive financial performance. Operational expansion and accreditation improvements also contribute to a positive outlook.
Krsnaa Diagnostics Limited has announced its financial results for the quarter and year ended March 31, 2026. The company reported a significant 102% year-on-year increase in Profit After Tax (PAT) to ₹417 crore for Q4 FY26, compared to ₹207 crore in Q4 FY25. This surge was driven by a 4% rise in revenue to ₹1,926 crore from ₹1,861 crore in the same period last year.
For the full fiscal year FY25-26, Krsnaa Diagnostics posted an 8% increase in revenue to ₹7,728 crore from ₹7,172 crore in FY24-25. PAT for the fiscal year grew by 31% to ₹1,013 crore from ₹776 crore in the previous year.
The company's EBITDA for Q4 FY26 increased by 3% to ₹559 crore, with the EBITDA margin remaining stable at 29%. For the full year, EBITDA grew by 10% to ₹2,149 crore, and the EBITDA margin improved to 28% from 27% in FY24-25.
Key operational highlights include a 74% increase in NABH Accreditation for Radiology Centres, reaching 54 centres. The network also saw an increase in CT/MRI centres to 149, pathology labs to 114, and patient collection centres to 4,762 in Q4 FY26.
The presentation also detailed the company's strategic vision, focusing on scale, awareness, and technology as growth drivers. Krsnaa Diagnostics aims to expand its network to over 200 CT/MRI centres and 5,000+ collection centres, solidifying its position as a leading integrated diagnostic service provider in India. The company emphasizes its commitment to affordable, quality diagnostics and leveraging technology, including AI, to enhance services.
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.